Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Daniel P. O'Day | Chairman & CEO | 7.27M | -- | 1964 |
Mr. Andrew D. Dickinson | Exec. VP & CFO | 2.94M | -- | 1970 |
Ms. Deborah H. Telman | Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. | 2.32M | -- | 1965 |
Ms. Johanna Mercier | Chief Commercial Officer | 3.32M | -- | 1970 |
Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer | 3.07M | -- | 1963 |
Ms. Sandra Patterson | Sr. VP, Corp. Controller & Principal Accounting Officer | -- | -- | 1967 |
Ms. Jacquie Ross C.F.A. | VP of Investor Relations | -- | -- | -- |
Ms. Jyoti K. Mehra | Exec. VP of HR | -- | -- | 1976 |
Dr. Linda Slanec Higgins Ph.D. | Sr. VP of Research, Innovation & Portfolio | -- | -- | 1962 |
Dr. Rudolf Ertl | Sr. VP of Commercial Operations of Australia, Canada, Europe | -- | -- | 1946 |
Gilead Sciences, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 17,000
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
Corporate Governance
Upcoming Events
April 24, 2025 at 8:00 PM UTC
Gilead Sciences, Inc. Earnings Date
Recent Events
September 14, 2023 at 12:00 AM UTC
Ex-Dividend Date